Prohibits any health insurer, pharmacy benefit manager, manufacturer or other third-party payor from discriminating against any 340B entity participating in a drug discount program.
H5634 creates the “Defending Affordable Prescription Drug Costs Act” and adds a new chapter to Rhode Island law governing businesses and professions. The bill is aimed at protecting entities participating in the federal 340B drug discount program, including 340B covered entities and their contract pharmacies, from being treated differently by health insurers, pharmacy benefit managers (PBMs), pharmaceutical manufacturers, or other third-party payors solely because of their 340B status.
The bill prohibits a wide range of practices that could disadvantage 340B participants, such as lower reimbursement rates, extra fees or conditions, network exclusion, special audit demands, claims-data requirements, restrictions on contract pharmacy use, and other contract terms that discriminate against 340B entities or patients choosing to receive drugs through them. It also bars manufacturers and their affiliates from interfering with the acquisition or delivery of 340B drugs to contract pharmacies, unless federal law allows it. The act excludes Medicaid reimbursement for covered outpatient drugs and includes a federal preemption clause to avoid conflict with federal law.
The bill also adds a reporting and oversight framework. Each 340B covered entity must file an annual report with the governor, legislative leaders, and the auditor general detailing acquisition costs, payments, vendor relationships, claim counts, program savings used for patient or community benefit, audits, and compliance information. The auditor general is given authority to investigate complaints and adopt rules, and violations are treated as deceptive trade practices and unfair sales practices under existing state law.
Overall, the sentiment reflected in the voting history appears strongly supportive, with the bill passing the House 69-2 and the Senate 36-0 on subsequent votes. That suggests broad legislative agreement with the goal of protecting access to discounted prescription drugs and preventing discriminatory reimbursement or contracting practices against 340B providers.
The main point of contention is likely the balance between protecting 340B entities and preserving flexibility for insurers, PBMs, and manufacturers to manage pharmacy networks, reimbursement, audits, and drug distribution. The bill attempts to address that concern by allowing preferred networks so long as 340B entities are not treated differently, and by preserving federal-law limits, but the reporting requirements and restrictions on manufacturer and payor conduct could still raise concerns about administrative burden, cost controls, and regulatory reach.
This act would add a new chapter to Title 5 of the Rhode Island General Laws and create enforceable state-law protections for 340B covered entities and 340B contract pharmacies. It would regulate conduct by health insurers, PBMs, pharmaceutical manufacturers, wholesalers, and other third-party payors by prohibiting discriminatory reimbursement, network exclusion, contract restrictions, and interference with 340B drug acquisition and dispensing. It also creates annual reporting obligations for 340B entities and authorizes the auditor general to investigate complaints and issue rules. Violations are tied to Rhode Island’s deceptive trade practices and unfair sales practices laws, expanding potential enforcement and penalties under existing consumer-protection statutes.
The available voting record indicates very strong support for the bill, with overwhelming passage in both chambers and only minimal opposition in the House. The lack of committee transcript material limits insight into detailed debate, but the final votes suggest the legislation was viewed favorably as a prescription-drug affordability and access measure. The overall tone is consistent with support for protecting safety-net providers and patients who rely on the 340B program.
The likely areas of contention involve whether the bill goes too far in limiting the business practices of PBMs, insurers, and manufacturers, especially regarding reimbursement methods, audits, claims data, and pharmacy network design. Opponents could argue that the bill constrains cost-management tools or creates compliance burdens, while supporters would view those restrictions as necessary to prevent discrimination against 340B participants and preserve patient access. The reporting requirements may also be seen as a transparency measure by supporters and an administrative burden by critics.